NEXLIZET Drug Patent Profile

« Back to Dashboard

Which patents cover Nexlizet, and what generic alternatives are available?

Nexlizet is a drug marketed by Esperion Theraps Inc and is included in one NDA. There are eight patents protecting this drug and one Paragraph IV challenge.

The generic ingredient in NEXLIZET is bempedoic acid; ezetimibe. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the bempedoic acid; ezetimibe profile page.

DrugPatentWatch^® Generic Entry Outlook for Nexlizet

Nexlizet was eligible for patent challenges on February 21, 2024.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be June 19, 2040. This may change due to patent challenges or generic licensing.

There have been ten patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for NEXLIZET

US Patents:	8
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Clinical Trials:	2
Drug Prices:	Drug price information for NEXLIZET
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for NEXLIZET
What excipients (inactive ingredients) are in NEXLIZET?	NEXLIZET excipients list
DailyMed Link:	NEXLIZET at DailyMed

See drug prices for NEXLIZET

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for NEXLIZET

NDA:

211617

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for NEXLIZET

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Louisville	PHASE4
Kaiser Permanente	Phase 4
Esperion Therapeutics, Inc.	Phase 4

See all NEXLIZET clinical trials

Pharmacology for NEXLIZET

Drug Class	Adenosine Triphosphate-Citrate Lyase Inhibitor Dietary Cholesterol Absorption Inhibitor
Mechanism of Action	Adenosine Triphosphate-Citrate Lyase Inhibitors
Physiological Effect	Decreased Cholesterol Absorption

Paragraph IV (Patent) Challenges for NEXLIZET

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
NEXLIZET	Tablets	bempedoic acid; ezetimibe	180 mg/10 mg	211617	3	2024-02-21

US Patents and Regulatory Information for NEXLIZET

NEXLIZET is protected by ten US patents and two FDA Regulatory Exclusivities.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Esperion Theraps Inc	NEXLIZET	bempedoic acid; ezetimibe	TABLET;ORAL	211617-001	Feb 26, 2020		RX	Yes	Yes
Esperion Theraps Inc	NEXLIZET	bempedoic acid; ezetimibe	TABLET;ORAL	211617-001	Feb 26, 2020		RX	Yes	Yes				Y
Esperion Theraps Inc	NEXLIZET	bempedoic acid; ezetimibe	TABLET;ORAL	211617-001	Feb 26, 2020		RX	Yes	Yes				Y
Esperion Theraps Inc	NEXLIZET	bempedoic acid; ezetimibe	TABLET;ORAL	211617-001	Feb 26, 2020		RX	Yes	Yes			Y
Esperion Theraps Inc	NEXLIZET	bempedoic acid; ezetimibe	TABLET;ORAL	211617-001	Feb 26, 2020		RX	Yes	Yes
Esperion Theraps Inc	NEXLIZET	bempedoic acid; ezetimibe	TABLET;ORAL	211617-001	Feb 26, 2020		RX	Yes	Yes

Expired US Patents for NEXLIZET

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Esperion Theraps Inc	NEXLIZET	bempedoic acid; ezetimibe	TABLET;ORAL	211617-001	Feb 26, 2020
Esperion Theraps Inc	NEXLIZET	bempedoic acid; ezetimibe	TABLET;ORAL	211617-001	Feb 26, 2020
Esperion Theraps Inc	NEXLIZET	bempedoic acid; ezetimibe	TABLET;ORAL	211617-001	Feb 26, 2020
Esperion Theraps Inc	NEXLIZET	bempedoic acid; ezetimibe	TABLET;ORAL	211617-001	Feb 26, 2020
Esperion Theraps Inc	NEXLIZET	bempedoic acid; ezetimibe	TABLET;ORAL	211617-001	Feb 26, 2020

EU/EMA Drug Approvals for NEXLIZET

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Daiichi Sankyo Europe GmbH	Nustendi	bempedoic acid, ezetimibe	EMEA/H/C/004959Nustendi is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:in combination with a statin in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin in addition to ezetimibealone in patients who are either statin-intolerant or for whom a statin is contraindicated, and are unable to reach LDL-C goals with ezetimibe alone,in patients already being treated with the combination of bempedoic acid and ezetimibe as separate tablets with or without statin	Authorised	no	no	no	2020-03-27

International Patents for NEXLIZET

When does loss-of-exclusivity occur for NEXLIZET?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

European Patent Office

Hungary

Israel

Japan

Mexico

South Korea

Spain

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering NEXLIZET around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2003299993	HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES
Brazil	0318046	Compostos de hidroxila e composições para controle de colesterol e empregos relacionados
Brazil	PI0318046	compostos de hidroxila, seu usos, e composições farmacêuticas
Canada	2513660	COMPOSES HYDROXYLES ET COMPOSITIONS DE REGULATION DU CHOLESTEROL ET UTILISATIONS ASSOCIEES (HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES)
Cyprus	1119404
Denmark	2404890

Supplementary Protection Certificates for NEXLIZET

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2404890	301062	Netherlands		PRODUCT NAME: BEMPEDONZUUR, OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT, HYDRAAT, SOLVAAT OF MENGSEL DAARVAN; REGISTRATION NO/DATE: EU/1/20/1424 20200331
2404890	LUC00174	Luxembourg		PRODUCT NAME: BEMPEDOIC ACID, OR A PHARMACEUTICALLY ACCEPTABLE SALT, HYDRATE, SOLVATE, OR MIXTURE THEREOF; AUTHORISATION NUMBER AND DATE: EU/1/20/1424 20200331
2404890	122020000048	Germany		PRODUCT NAME: BEMPEDOINSAEURE ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ, HYDRAT, SOLVAT ODER EIN GEMISCH DAVON; REGISTRATION NO/DATE: EU/1/20/1424 20200327
2404890	132020000000112	Italy		PRODUCT NAME: ACIDO BEMPEDOICO, O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE, IDRATO, SOLVATO, O LORO MISCELA(NUSTENDI); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/20/1424, 20200331
2404890	2020C/534	Belgium		PRODUCT NAME: ACIDE BEMPEDOIQUE OU UN SEL, HYDRATE, PRODUIT DE SOLVATATION OU MELANGE DE CEUX-CI, PHARMACEUTIQUEMENT ACCEPTABLES; AUTHORISATION NUMBER AND DATE: EU/1/20/1424 20200331
2404890	CA 2020 00041	Denmark		PRODUCT NAME: BEMPEDOINSYRE ELLER ET/EN FARMACEUTISK ACCEPTABEL(T) SALT, HYDRAT, SOLVAT ELLER BLANDING DERAF; REG. NO/DATE: EU/1/20/1424 20200331

NEXLIZET Market Dynamics, Financial Trajectory, Patent Exclusivity and Generic Risk

Last updated: October 26, 2026

NEXLIZET is Esperion Therapeutics' fixed-dose combination of bempedoic acid and ezetimibe for LDL-cholesterol reduction. Its commercial outlook depends on three factors: expansion beyond statin-intolerant patients, adoption of oral nonstatin therapies after cardiovascular-outcomes data, and the ability to defend bempedoic-acid intellectual property against generic competition.

Esperion reports NEXLIZET together with NEXLETOL, its single-ingredient bempedoic-acid product. Public filings therefore do not provide a complete standalone NEXLIZET revenue series. The combined franchise has moved from a launch-stage product in 2020 to Esperion's primary commercial asset, supported by the CLEAR Outcomes trial and expanded payer access.

What is NEXLIZET and how does it compete in cholesterol treatment?

NEXLIZET combines bempedoic acid and ezetimibe in a once-daily oral tablet.

Product	Active ingredients	FDA indication	Manufacturer	Administration
NEXLIZET	Bempedoic acid 180 mg plus ezetimibe 10 mg	Adjunct to diet and maximally tolerated statin therapy to reduce LDL-C	Esperion Therapeutics	One tablet daily
NEXLETOL	Bempedoic acid 180 mg	LDL-C reduction and cardiovascular-risk reduction in defined high-risk patients	Esperion Therapeutics	One tablet daily
Zetia	Ezetimibe 10 mg	LDL-C reduction	Merck legacy product; generic versions available	One tablet daily
Repatha	Evolocumab	LDL-C reduction and cardiovascular-risk reduction	Amgen	Injection
Praluent	Alirocumab	LDL-C reduction and cardiovascular-risk reduction	Regeneron/Sanofi	Injection
Leqvio	Inclisiran	LDL-C reduction	Novartis	Injection twice yearly after loading

NEXLIZET's commercial proposition is the combination of two oral mechanisms. Bempedoic acid inhibits ATP citrate lyase upstream of HMG-CoA reductase. Ezetimibe reduces intestinal cholesterol absorption. The combination is intended to produce greater LDL-C lowering than either component alone.

NEXLIZET is most differentiated in patients who cannot reach LDL-C targets with statins or who cannot tolerate adequate statin intensity. It competes with generic ezetimibe, high-intensity statins, PCSK9 antibodies, inclisiran and other emerging oral lipid-lowering drugs.

What FDA regulatory milestones define NEXLIZET's exclusivity timeline?

The FDA approved NEXLIZET on May 28, 2020. The product was approved as a fixed-dose combination containing bempedoic acid, the active ingredient in NEXLETOL, and ezetimibe, the active ingredient in Zetia.[1]

Milestone	Date	Commercial significance
NEXLETOL FDA approval	Feb. 21, 2020	Established bempedoic acid as a new oral LDL-lowering therapy
NEXLIZET FDA approval	May 28, 2020	Added the fixed-dose bempedoic acid/ezetimibe combination
CLEAR Outcomes trial results	March 2023	Demonstrated cardiovascular-event reduction in statin-intolerant patients
FDA expanded NEXLETOL label	March 2024	Added reduction of major adverse cardiovascular events in high-risk patients
Current strategic focus	2024 onward	Shift from LDL-C lowering alone toward outcomes-based cardiovascular prevention

Bempedoic acid received new-chemical-entity exclusivity associated with its initial FDA approval. That period did not provide permanent protection against generic bempedoic acid or fixed-dose combination products. NEXLIZET's separate fixed-combination and formulation protections are more important to the product's post-exclusivity position.

What patents protect NEXLIZET?

NEXLIZET protection is based on a combination of patents covering bempedoic acid, pharmaceutical compositions, fixed-dose combinations, formulations and methods of use. The relevant patent estate is broader than a single composition-of-matter patent.

Composition and formulation patents

The main patent categories include:

• Bempedoic-acid compound and related active pharmaceutical ingredient claims.
• Pharmaceutical compositions containing bempedoic acid.
• Fixed-dose combinations of bempedoic acid and ezetimibe.
• Oral dosage forms and formulation parameters.
• Methods for lowering LDL cholesterol.
• Methods for treating patients with statin intolerance or elevated cardiovascular risk.
• Cardiovascular-risk reduction associated with bempedoic-acid therapy.

Patent terms vary by patent, filing date, patent-term adjustment, patent-term extension and the scope of the claims. The earliest loss of protection for one patent does not necessarily create an immediate lawful launch opportunity if later-expiring combination or method-of-use patents remain enforceable.

Orange Book status

NEXLIZET is listed under FDA NDA 211617. The Orange Book is the controlling public source for patents submitted to FDA for the product. NEXLETOL is listed separately under NDA 211616.[2]

Orange Book listings can change through patent delistings, corrections, expiration updates and new patent submissions. The commercial question is not only whether a patent is listed, but whether a generic applicant can certify that the listed claims are invalid, unenforceable or not infringed.

Publicly available company disclosures indicate that Esperion has relied on an estate extending beyond the initial five-year new-chemical-entity period. Exact generic-entry timing depends on the patents listed for the relevant NDA and the certifications made by each abbreviated new drug application applicant.

When does NEXLIZET lose exclusivity?

NEXLIZET does not have one single loss-of-exclusivity date.

The practical exclusivity sequence is:

1. The bempedoic-acid new-chemical-entity period began with the first approval of NEXLETOL in February 2020.
2. The NCE period protected FDA approval of products containing bempedoic acid for five years, subject to the statutory framework governing abbreviated applications.
3. NEXLIZET's three-year exclusivity associated with the fixed-dose combination and supporting clinical investigations did not provide a long-term barrier comparable to a new active ingredient.
4. Patent protection may extend beyond regulatory exclusivity.
5. Generic entry requires an approved ANDA, a permissible patent certification and resolution of any litigation or stay.

The first meaningful generic threat is likely to come from separate bempedoic-acid products and fixed-dose bempedoic-acid/ezetimibe products. Generic ezetimibe already limits the pricing power of the combination because physicians can prescribe the two ingredients separately.

Which companies are challenging NEXLIZET?

The principal challengers are expected to be generic manufacturers pursuing ANDAs for bempedoic acid and bempedoic-acid/ezetimibe combinations. The competitive set includes large generic companies such as Teva, Viatris, Sandoz, Dr. Reddy's Laboratories, Sun Pharmaceutical and Amneal, although the identity and timing of actual NEXLIZET ANDA filers must be assessed from FDA and court records rather than inferred from industry participation.

Generic challenge risk has several forms:

Challenge type	Product target	Expected commercial effect
Bempedoic-acid monotherapy	NEXLETOL equivalent	Erodes single-agent franchise and may reduce combination pull-through
Fixed-dose combination	NEXLIZET equivalent	Direct substitution and price competition
Ezetimibe substitution	Generic ezetimibe plus bempedoic acid	Weakens the convenience premium of one-tablet therapy
Paragraph IV certification	Listed patent claims	Can trigger patent litigation and a statutory 30-month stay
Paragraph III certification	Later patent expiry	Defers launch until the stated expiry date

A Paragraph IV filing does not establish that a generic will launch. Esperion can sue within 45 days of receiving notice, triggering the statutory stay. The outcome depends on infringement, validity and enforceability findings for each asserted patent.

What is the financial trajectory of NEXLIZET and the Esperion franchise?

Esperion's public reporting combines NEXLIZET and NEXLETOL net product revenue. That reporting convention prevents a precise public calculation of NEXLIZET's standalone sales.

The franchise trajectory has nevertheless been clear:

• Initial uptake was constrained by low awareness, payer restrictions and the absence of cardiovascular-outcomes data.
• Prescription demand improved after the CLEAR Outcomes trial showed a reduction in major cardiovascular events among statin-intolerant patients.
• Commercial performance benefited from broader payer access and a shift from a purely LDL-C-lowering message to cardiovascular-risk reduction.
• The fixed-dose combination remains important because it improves convenience relative to prescribing separate bempedoic acid and ezetimibe tablets.
• Revenue growth is exposed to gross-to-net discounts, rebates, patient assistance and the company's decision to prioritize access over list-price expansion.

Financial driver	Effect on NEXLIZET
CLEAR Outcomes data	Expands the addressable evidence-based treatment population
Primary-care adoption	Critical for volume beyond lipid specialists
Statin intolerance diagnosis	Determines patient eligibility and prescribing confidence
Generic ezetimibe	Pressures the combination's price premium
Payer coverage	Controls initiation and refill persistence
Direct-to-consumer promotion	Can increase awareness but raises acquisition cost
Fixed-dose convenience	Supports adherence and differentiation
Generic bempedoic acid	Creates the largest long-term revenue threat

Esperion's business has historically depended heavily on the bempedoic-acid franchise. This concentration creates operating leverage when prescriptions grow, but it also increases financial risk if pricing weakens or a generic challenge accelerates entry.

How important are cardiovascular outcomes to NEXLIZET demand?

The CLEAR Outcomes trial changed the commercial basis for bempedoic acid. The trial evaluated statin-intolerant patients at high cardiovascular risk and reported a statistically significant reduction in major cardiovascular events with bempedoic acid compared with placebo.[3]

Before those data, NEXLIZET competed largely on LDL-C reduction and oral administration. After the trial, Esperion could position bempedoic acid as an outcomes-supported therapy for patients unable or unwilling to take statins.

The evidence supports use in a defined population, not unrestricted replacement of statins. Statins remain the standard first-line therapy for most patients because of their clinical evidence, low cost and broad guideline adoption. NEXLIZET's opportunity is concentrated in patients with inadequate LDL-C control, statin intolerance, high cardiovascular risk or a need for additional oral therapy.

What generic entry risks exist for NEXLIZET?

The largest risk is a two-stage erosion process.

First, generic bempedoic acid could reduce the value of NEXLETOL and make separate-pill therapy with generic ezetimibe more attractive. Second, a generic fixed-dose combination could directly compete with NEXLIZET on price and formulary status.

The fixed-dose product has some protection against immediate substitution because a generic bempedoic-acid tablet and generic ezetimibe are not therapeutically identical to a single combination tablet from a dispensing perspective. That protection is commercial rather than absolute. Payers can encourage separate-pill substitution, and prescribers can write the components separately.

Potential launch scenarios are:

Scenario	Timing	Revenue impact
No successful Paragraph IV challenge	After relevant patent expiry	Gradual erosion at ordinary LOE
Patent settlement with delayed launch	Contractual date before or after expiry	Predictable but potentially earlier erosion
Court invalidation or non-infringement ruling	Before patent expiry	Rapid price and share decline
Separate-component generic entry	Before fixed-dose entry	Pressure on NEXLIZET pricing and adherence value
Multiple generic entrants	After first launch	Steepest net-price compression

How strong is the NEXLIZET patent estate?

The estate is stronger commercially than a single-product formulation patent because it combines active-ingredient, combination and method-of-use positions. Its weaknesses are also material:

• Bempedoic acid is a small molecule, making conventional generic development feasible.
• Ezetimibe is already generic.
• Fixed-dose combination development is less complex than biologic interchangeability.
• Method-of-use claims may be vulnerable if generic labels omit protected language.
• Patent validity challenges can target obviousness, written description, enablement and double-patenting.
• Separate-pill substitution can bypass some of the commercial value of the combination.

The estate's effective strength therefore depends on claim scope, patent expiration sequencing and the willingness of generic applicants to accept a label carve-out or pursue litigation.

Does NEXLIZET face biosimilar risk?

No. NEXLIZET is a chemically synthesized small-molecule tablet, not a biologic. It is exposed to ANDA-based generic competition, not biosimilar competition under the Public Health Service Act.

Its closest biologic competitors are PCSK9 antibodies and inclisiran. Those products create market pressure through clinical efficacy, payer contracting and route-of-administration differences, but they do not enter through the NEXLIZET generic pathway.

What licensing deals affect NEXLIZET?

Esperion has used commercialization and licensing arrangements to expand access outside the United States. The company has entered regional and global agreements involving bempedoic acid products, including arrangements with Daiichi Sankyo in Europe and other territories.[4]

Licensing provides milestone, royalty and commercial-partner revenue, but it also reduces the share of end-market economics retained by Esperion. The commercial value depends on territory, transfer price, royalty rate, regulatory responsibility and whether the partner has established cardiovascular sales infrastructure.

In the United States, Esperion retains the central economic exposure to NEXLIZET and NEXLETOL. International arrangements diversify regulatory and selling costs but can make reported revenue less directly comparable across periods.

What is the commercial outlook for NEXLIZET?

NEXLIZET has a credible growth path while the product remains protected and payer access expands. The addressable population is large because dyslipidemia is common, but the treated segment is narrower: patients who require additional LDL-C lowering, cannot tolerate adequate statin therapy or need an oral alternative to injectable agents.

The main upside drivers are:

• Greater primary-care prescribing.
• Wider recognition of statin intolerance.
• Use in patients with established cardiovascular disease.
• Improved reimbursement after outcomes-based label expansion.
• Conversion from separate bempedoic-acid and ezetimibe tablets to the fixed-dose product.
• International uptake through licensing partners.

The main downside drivers are:

• Generic or low-cost ezetimibe substitution.
• Generic bempedoic-acid entry.
• Payer restrictions and prior authorization.
• Competition from PCSK9 therapies and inclisiran.
• High patient acquisition costs.
• Dependence on one active commercial franchise.

Key Takeaways

• NEXLIZET is Esperion's fixed-dose bempedoic acid/ezetimibe product, approved by FDA in May 2020.
• Esperion reports NEXLIZET and NEXLETOL revenue together, so standalone NEXLIZET sales are not fully disclosed.
• CLEAR Outcomes and the 2024 FDA label expansion improved the product's cardiovascular-risk-reduction positioning.
• NEXLIZET has no biosimilar risk because it is a small-molecule tablet.
• Generic risk will likely emerge through bempedoic-acid monotherapy, fixed-dose combination products or separate-pill substitution with generic ezetimibe.
• Patent value depends on the interaction of active-ingredient, formulation, combination and method-of-use claims.
• The principal commercial variable is whether outcomes-based adoption outpaces payer pressure and generic substitution.

FAQs About NEXLIZET Exclusivity and Market Competition

Is NEXLIZET more effective than ezetimibe alone?

NEXLIZET generally produces greater LDL-C reduction than ezetimibe alone because it combines ezetimibe with bempedoic acid. The appropriate choice depends on cardiovascular risk, statin tolerance, treatment response and payer coverage.

Can a generic manufacturer copy NEXLIZET?

A generic manufacturer can seek FDA approval for an equivalent bempedoic-acid/ezetimibe combination through an ANDA. Approval and launch depend on patent certifications, litigation and any applicable regulatory exclusivity.

Is NEXLIZET a biologic drug?

No. NEXLIZET is an oral, chemically synthesized small-molecule combination. Generic manufacturers use the ANDA pathway rather than the biosimilar pathway.

Why is NEXLIZET commercially important if ezetimibe is generic?

The product combines two mechanisms in one tablet and adds bempedoic acid's cardiovascular-outcomes evidence. The convenience and clinical positioning can support use despite the availability of low-cost generic ezetimibe.

What is the biggest long-term threat to NEXLIZET revenue?

The largest threat is generic bempedoic-acid competition combined with separate-pill use of generic ezetimibe. That pathway could reduce both NEXLIZET's price premium and the economic value of its one-tablet format.

References

1. U.S. Food and Drug Administration. (2020). FDA approves Nexlizet for treatment of hypercholesterolemia. FDA.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
3. Nissen, S. E., Lincoff, A. M., Brennan, D., et al. (2023). Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. New England Journal of Medicine, 388(15), 1353-1364.
4. Esperion Therapeutics, Inc. (2024). Annual report on Form 10-K for the fiscal year ended December 31, 2023. U.S. Securities and Exchange Commission.

DrugChatter Q&A for NEXLIZET

Nexlizet patient reviews?
Nexlizet tablet?
Is there a generic for nexlizet?